However, anlotinib given concurrently with PD-1/PD-L1 inhibitors as first or second-line maintenance therapy for ES-SCLC demonstrated encouraging efficacy and an acceptable safety profile: median PFS was 8.2 months, OS 20.1 months, and the ORR reached 50.0% in a single-center retrospective study (131). This evidence concerns the gene CD274 and small cell lung carcinoma.